Genentech, a member of the Roche, announced the FDA has approved the Vabysmo 6.0 mg single-dose prefilled syringe, or PFS, for use in the treatment of wet, or neovascular, age-related macular degeneration, or AMD, diabetic macular edema, or DME, and macular edema following retinal vein occlusion, or RVO. Together, these three conditions affect close to three million people in the U.S. The Vabysmo PFS will become available to U.S. retina specialists and their patients in the coming months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
- Roche price target raised to CHF 250 from CHF 240 at Jefferies
- Genentech treatment of hemophilia A granted FDA orphan status
- Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
- CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition